Despite the difference in organs and cancer types, this result is highly consistent with previous studies in which patients with abundant stromal myofibroblasts expressing SMA showed a poorer prognosis in oral, colorectal and breast cancers.[26]–[29] Our results also showed that patients expressing FSP1 were older and had shorter survival rates, which was also consistent with previous studies performed on breast cancer.[30] PDGFRβ expression was associated with poorly differentiated tumors (p = 0.010) but was not associated with prognosis. The gene discussed is S100A4; the disease is breast cancer.